Treatment Advancements in Newly Diagnosed and Relapsed/Refractory in Multiple Myeloma - Episode 4
CEPHEUS Subgroup Analyses: Insights From ASCO 2025
Panelists analyses from the CEPHEUS suggest that quadruplet regimens provide broad benefits in transplant-ineligible patients, though ultra–high-risk subtypes may require novel strategies discuss how subgroup.
Quadruplets for Older Patients and High-Risk Cytogenetics
Recent analyses from the IFM and EMN studies suggest that quadruplet therapy benefits not just younger, fit patients, but also those who are older or considered transplant-deferred. These findings challenge traditional categorizations of transplant eligibility.
In-depth subgroup analyses show that the benefits of quad therapy extend across ISS staging and age groups. However, patients with ultra–high-risk cytogenetics (eg, del(17p), t(4;14)) continue to experience poor outcomes even with enhanced induction, indicating persistent unmet needs.
Clinicians now consider early use of novel agents and dual maintenance strategies for high-risk, nontransplant candidates. A more nuanced approach to treatment planning is emerging, guided by cytogenetic profiles and functional assessments rather than strict age cutoffs.
Related Content:
